Phase 3 vaccine trials are challenging to design in epidemics, such as Ebola. A mechanistic transmission model allowed more accurate estimation of declining incidence. Mechanistic models can include change in incidence caused by the use of an effective vaccine. Changes in likely trial feasibility were updated in real time as the epidemic progressed.